Transcription of US-56427 ---------------------------- DOSAGE AND ...
{{id}} {{{paragraph}}}
Example: marketing
US-56427 ---------------------------- DOSAGE AND ...
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use BRILINTA safely and effectively. See full prescribing information for (ticagrelor) tablets, for oral use Initial Approval: 2011 WARNING: (A) BLEEDING RISK, and (B) ASPIRIN DOSE AND BRILINTA EFFECTIVENESS IN PATIENTS WITH ACSSee full prescribing information for complete boxed RISK BRILINTA, like other antiplatelet agents, can cause significant, sometimes fatal bleeding. ( , ) Do not use BRILINTA in patients with active pathological bleeding or a history of intracranial hemorrhage. ( , ) Do not start BRILINTA in patients undergoing urgent coronary artery bypass graft surgery (CABG). ( , ) If possible, manage bleeding without discontinuing BRILINTA.
is contraindicated in patients with hypersensitivity (e.g., angioedema) to ticagrelor or any component of the product. 5: WARNINGS AND PRECAUTIONS 5.1 : Risk of Bleeding: Drugs that inhibit platelet function including BRILINTA increase the risk of bleeding [see
Loading..
Tags:
Information
Domain:
Source:
Link to this page:
Please notify us if you found a problem with this document: